Cutera, Inc. (NASDAQ:CUTR) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

CUTR has been the subject of a number of other research reports. Roth Capital increased their target price on Cutera from $32.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday. Sidoti restated a “buy” rating and issued a $30.00 target price (up previously from $27.00) on shares of Cutera in a report on Saturday, June 3rd. Zacks Investment Research lowered Cutera from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. TheStreet lowered Cutera from a “b-” rating to a “c” rating in a report on Monday, May 1st. Finally, Maxim Group restated a “buy” rating and issued a $33.00 target price (up previously from $27.00) on shares of Cutera in a report on Thursday, July 13th. Six analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $33.25.

Shares of Cutera (CUTR) opened at 34.10 on Friday. The stock has a 50 day moving average price of $27.16 and a 200-day moving average price of $22.41. The stock has a market cap of $477.57 million, a P/E ratio of 73.33 and a beta of 0.60. Cutera has a 12 month low of $10.54 and a 12 month high of $34.91.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.10. Cutera had a return on equity of 11.64% and a net margin of 5.07%. The company had revenue of $36.40 million during the quarter, compared to the consensus estimate of $32.08 million. During the same quarter in the prior year, the firm earned $0.07 EPS. The company’s quarterly revenue was up 32.4% compared to the same quarter last year. On average, analysts forecast that Cutera will post $0.55 EPS for the current fiscal year.

Cutera announced that its board has initiated a share buyback plan on Monday, August 7th that allows the company to repurchase $25.00 million in shares. This repurchase authorization allows the medical device company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/cutera-inc-cutr-lifted-to-buy-at-bidaskclub/1477530.html.

In other news, CFO Ronald J. Santilli sold 3,857 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $22.95, for a total value of $88,518.15. Following the completion of the sale, the chief financial officer now owns 88,321 shares in the company, valued at $2,026,966.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David A. Gollnick sold 10,000 shares of the stock in a transaction on Monday, June 26th. The shares were sold at an average price of $25.08, for a total value of $250,800.00. Following the completion of the sale, the director now owns 26,641 shares of the company’s stock, valued at approximately $668,156.28. The disclosure for this sale can be found here. Insiders sold 64,563 shares of company stock valued at $1,485,360 in the last 90 days. Corporate insiders own 11.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in CUTR. American International Group Inc. increased its position in Cutera by 7.0% in the first quarter. American International Group Inc. now owns 7,221 shares of the medical device company’s stock worth $149,000 after buying an additional 475 shares during the period. Nationwide Fund Advisors increased its position in Cutera by 8.4% in the second quarter. Nationwide Fund Advisors now owns 7,216 shares of the medical device company’s stock worth $187,000 after buying an additional 561 shares during the period. Metropolitan Life Insurance Co. NY bought a new position in Cutera during the first quarter worth $202,000. PNC Financial Services Group Inc. bought a new position in Cutera during the second quarter worth $241,000. Finally, Citadel Advisors LLC bought a new position in Cutera during the second quarter worth $245,000. Institutional investors own 82.87% of the company’s stock.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.